이스라엘 - 히브리어 - Ministry of Health

unipharm ltd, israel - donepezil hydrochloride - טבליה - donepezil hydrochloride 5 mg - anticholinesterases - treatment of mild to moderately severe alzheimer`s dementia.

이스라엘 - 히브리어 - Ministry of Health

pfizer pharmaceuticals israel ltd - dexmedetomidine hydrochloride 0.5 mg/ml - solution for injection - non-invasive mildly to moderately painful procedures and examinations which require restraint sedation and analgesia in dogs and cats. premedication in cats before induction and maintenance of general anaesthesia with ketamine. deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures. premedication in dogs before induction and maintenance of general anaesthesia.

이스라엘 - 히브리어 - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pfs - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

이스라엘 - 히브리어 - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - vial - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r